Skip to main content

Table 1 Clinically detectable injection site swelling

From: Safety of an extended-release injectable moxidectin suspension formulation (ProHeart® 12) in dogs

Injection site

Groupa

Degree of swellingb

Day of study

1

8

57

120

183

190

239

302

365

372

379

Day 1

Controlc

None

6

6

8

8

8

8

8

8

6

8

8

Very slight

2

2

2

0.5 mg/kg

None

8

8

8

8

8

8

8

8

8

8

1.5 mg/kg

None

8

8

6

5

4

6

6

1

1

4

Very slight

2

2

2

1

3

3

3

Slight

1

2

1

2

4

4

1

2.5 mg/kg

None

6

7

7

3

7

7

4

1

1

5

Very slight

2

1

1

3

2

2

3

1

Slight

2

1

1

2

5

4

2

Day 183

Control

None

8

7

7

8

7

8

8

Very slight

1

Slight

1

1

0.5 mg/kg

None

7

8

8

8

6

5

8

Very slight

2

2

Slight

1

1

1.5 mg/kg

None

8

6

6

5

3

2

4

Very slight

1

1

1

2

4

Slight

1

1

3

4

4

2.5 mg/kg

None

8

8

8

3

1

1

3

Very slight

4

2

1

3

Slight

1

5

6

2

Day 364

Control

None

8

0.5 mg/kg

None

8

1.5 mg/kg

None

3

Very slight

4

Slight

1

2.5 mg/kg

None

3

Very slight

3

Slight

2

  1. aControl animals 0.9% sodium chloride (saline) solution. All other animals received ProHeart® 12. n = 8 for all groups
  2. b‘Very slight’ is defined as ‘barely perceptible’. ‘Slight’ is defined as ‘edges of area well-defined by definite raising’
  3. –, no dogs with this categorization